Table 4.

Percent time in range (70–180 mg/dL) by group according to baseline factors

	CGM-only group (n = 148)*			CGM+BGM group (n = 76)*
	n	Baseline	26-Week study period	n	Baseline	26-Week study period	P value for interaction†
Age							0.08
<50 years	94	60 ± 13	60 ± 13	45	65 ± 13	65 ± 13
≥50 years	54	68 ± 12	67 ± 12	31	64 ± 11	65 ± 9
Diabetes duration							0.74
<25 years	87	62 ± 13	63 ± 12	41	67 ± 12	66 ± 11
≥25 years	61	63 ± 14	63 ± 14	35	62 ± 13	63 ± 12
Education‡							0.71
Less than bachelor’s degree	34	59 ± 14	59 ± 13	12	65 ± 9	63 ± 11
Bachelor’s degree or higher	113	64 ± 13	64 ± 13	61	66 ± 13	65 ± 11
CGM use before study
Never used	25	64 ± 12	65 ± 10	14	65 ± 10	63 ± 13	0.26
In past, but not current	54	58 ± 13	57 ± 14	24	62 ± 14	63 ± 13
Current Dexcom user	49	67 ± 12	67 ± 12	28	69 ± 12	68 ± 10
Current Medtronic user	20	64 ± 13	63 ± 11	10	59 ± 8	61 ± 7
Baseline HbA1c							0.20
<7.5% (58 mmol/mol)	108	67 ± 11	66 ± 11	60	69 ± 10	68 ± 9
≥7.5% (58 mmol/mol)	40	51 ± 10	52 ± 12	16	50 ± 9	52 ± 10
Baseline time in range (70–180 mg/dL)							0.39
<60%	61	50 ± 8	53 ± 11	24	51 ± 7	54 ± 9
≥60%	87	72 ± 8	69 ± 10	52	72 ± 8	69 ± 9

Data are mean ± SD unless otherwise noted.

*One participant in the CGM-only group and one in the CGM+BGM group never came in for a follow-up visit and therefore had no CGM data;

†P values obtained by including an interaction term in each ANCOVA model adjusted for baseline value and site as a random effect. Continuous variable used in the models for age, duration, HbA_1c, and baseline time in range;

‡education missing for one participant in the CGM-only group and three participants in the CGM+BGM group.